HALO : Analysis & Opinions

  1. Halozyme Estimates 2017 Revenue of $115M to $130M

    January 11, 2017
    Halozyme expects 2017 revenue of $115 million to $130 million, below the $135 million it made in 2015.
  2. Halozyme Pancreatic Cancer Drug Succeeds in Trial

    January 6, 2017
    Halozyme said its PEGPH20 pancreatic cancer drug did well in a mid-stage combo drug study.
  3. AbbVie Ends Halozyme Enhanze Development Program (HALO, ABBV)

    November 22, 2016
    AbbVie ended a drug development partnership with Halozyme Therapeutics after a failed study.
  4. Halozyme 3Q Loss $29M, or 23 Cents a Share (HALO)

    November 9, 2016
    Halozyme reported a third-quarter loss of 23 cents a share, beating analyst projections.
  5. How Halozyme Uses Enzymes to Deliver Drugs (HALO)

    September 19, 2016
    Halozyme's use of enzymes to deliver drugs under the skin could win longterm, but profits may be years away